Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Biedenkopf – page 35

454 clinical trials in Biedenkopf, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Biedenkopf at a glance
454
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

454 trials in Biedenkopf

Open in trial search

Study of Tuvusertib and Cemiplimab for Patients with Non-Squamous Non-Small Cell Lung Cancer After Previous Treatments

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Merck Healthcare KGaA

Study on the Effects of Briquilimab in Adults with Chronic Spontaneous Urticaria Unresponsive to Antihistamines

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Briquilimab
  • Sponsor:Jasper Therapeutics Inc.

Urticaria chronic

Not recruiting

Study on Briquilimab for Adults with Chronic Inducible Urticaria Unresponsive to H1-Antihistamines

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Briquilimab
  • Sponsor:Jasper Therapeutics Inc.

Study Comparing Nivolumab to Placebo for Patients with High-Risk Invasive Bladder Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study on Ribociclib and Drug Combination for Patients with Advanced HER2-Negative, Hormone Receptor Positive Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Institut Für Frauengesundheit GmbH

Plasma cell myeloma

Not recruiting

Study on Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Low-Risk Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Partial seizures

Not recruiting

Study on ENX-101 for Treating Focal Epilepsy in Patients Using 1 to 4 Antiseizure Medications

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:ENX-101
  • Sponsor:Engrail Therapeutics Inc.

Study of Pembrolizumab as Additional Treatment for Patients with High-Risk Locally Advanced Cutaneous Squamous Cell Carcinoma After Surgery and Radiation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Hepatitis D

Not recruiting

Study on Bulevirtide Treatment for Patients with Chronic Hepatitis D

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bulevirtide
  • Sponsor:Gilead Sciences Inc.

Study on the Safety and Effectiveness of MK-5475 for Adults with Pulmonary Hypertension and COPD

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Frespaciguat
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Safety and Effectiveness of Stereotactic Body Radiotherapy with or without Pembrolizumab for Patients with Unresected Stage I or II Non-Small Cell Lung Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study of Telisotuzumab Vedotin for Adults with Advanced Non-Squamous Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Telisotuzumab Vedotin
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.